Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronary Atherosclerosis Progression with Testosterone InterVEntion (CAPTIVE): a randomised double blind placebo-controlled non-inferiority trial in middle-aged to older men.

Next Previous
Trial Profile

Coronary Atherosclerosis Progression with Testosterone InterVEntion (CAPTIVE): a randomised double blind placebo-controlled non-inferiority trial in middle-aged to older men.

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms CAPTIVE

Most Recent Events

  • 03 Feb 2022 Planned number of patients changed from 150 to 558.
  • 03 Feb 2022 Planned initiation date changed from 1 Jul 2021 to 1 Jul 2022.
  • 03 Feb 2022 According to the Australian New Zealand Clinical Trials Registry record protocol has been amended as there is change in official title and in primary end points.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top